Core Viewpoint - Dongshan Precision plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy, brand recognition, and overall competitiveness [2]. Group 1: H-share Issuance - The company aims to raise funds for project production, new capacity construction, technological transformation, loan repayment, and general corporate purposes [3]. - The base issuance scale is set at no more than 10% of the total share capital post-issuance, with an overallotment option of up to 15% [3]. Group 2: Shareholder Actions - The controlling shareholder, Yuan Yongfeng, has released a pledge on 33.72 million shares, accounting for 1.84% of the total share capital [4]. - As of the announcement date, Yuan Yongfeng and his associates hold a total of 33.26% of the company's shares, with 17.57 million shares pledged, representing 9.59% of the total share capital [4]. Group 3: Risk Management - The company states that the release of the pledge does not involve new financing arrangements and that the pledge risk is under control [5]. - In case of any potential pledge risks, the controlling shareholder will consider measures such as additional pledges, guarantees, and margin deposits [6].

Core Viewpoint - The China Securities Regulatory Commission has confirmed the overseas listing applications for five companies, all of which are set to list in Hong Kong, with two of them already listed in the US market [1][4]. Group 1: Company Summaries - **Xiaoma Zhixing** plans to issue up to 102,146,500 ordinary shares for listing on the Hong Kong Stock Exchange. The company is headquartered in Guangzhou and specializes in autonomous driving systems for taxis and trucks. As of the first half of 2025, it reported revenues of $35.43 million and a net loss of $96.09 million [1][4][5]. - **Wenyan Zhixing** intends to issue up to 102,428,200 ordinary shares for its Hong Kong listing. The company develops autonomous driving systems and software, holding licenses in seven countries. In the first half of 2025, it reported revenues of $2 billion and a net loss of $7.92 billion [1][6][5]. - **Yujian Xiaomian** aims to issue up to 235,108,000 ordinary shares for its Hong Kong listing. The company operates a chain of Chinese restaurants, primarily offering Chongqing noodles. As of April 5, 2025, it had 374 restaurants in mainland China and 6 in Hong Kong. Revenue figures from 2022 to 2024 were $418 million, $801 million, and $1.154 billion, with corresponding net profits of -$35.97 million, $45.91 million, and $60.70 million [1][8][5]. - **Qingsong Jiankang** plans to issue up to 36,496,400 ordinary shares for its Hong Kong listing. The company provides digital health services and health insurance solutions. Revenue figures from 2022 to 2025 were $394 million, $490 million, $945 million, and $656 million, with net profits of -$9.10 million, $97.17 million, $8.99 million, and $86.05 million [1][10][5]. - **Tudatong** intends to merge with TechStar Acquisition Corporation to achieve a listing on the Hong Kong Stock Exchange, issuing up to 190,240,000 ordinary shares. The company specializes in the development and production of automotive-grade lidar for advanced driving assistance systems and autonomous driving. Revenue figures from 2022 to 2024 were $66.30 million, $121 million, and $160 million, with net losses of $188 million, $219 million, and $398 million [1][11][5].

Core Viewpoint - Mindray Medical (300760.SZ) plans to issue overseas listed foreign shares (H-shares) and list on the main board of the Hong Kong Stock Exchange to enhance its capital strength and support its internationalization strategy [1] Group 1 - The company aims to deepen its international strategy and create an international capital operation platform [1] - The issuance will consider the interests of existing shareholders and the conditions of domestic and foreign capital markets [1] - The company will complete the issuance and listing within 24 months after the shareholders' meeting resolution or within an extended period if agreed [1]

格隆汇10月14日丨迈瑞医疗(300760.SZ)公布，为满足公司业务发展需要，深入推进国际化战略，打造 国际化资本运作平台，进一步提升公司资本实力，经公司充分研究论证，公司拟发行境外上市外资股 （H股）股票并在香港联合交易所有限公司（简称"香港联交所"）主板挂牌上市。公司将充分考虑现有 股东的利益和境内外资本市场的情况，在股东会决议有效期内（即经公司股东会审议通过之日起24个月 或同意延长的其他期限）选择适当的时机和发行窗口完成本次发行并上市。 ...

北京商报讯（记者 丁宁）10月14日晚间，迈瑞医疗（300760）发布公告称，公司于10月14日召开第八 届董事会第十四次会议，审议通过了《关于公司发行H股股票并在香港联合交易所有限公司上市的议 案》《关于公司发行H股股票并在香港联合交易所有限公司上市方案的议案》等相关议案。 迈瑞医疗表示，为满足公司业务发展需要，深入推进国际化战略，打造国际化资本运作平台，进一步提 升公司资本实力，经公司充分研究论证，公司拟发行境外上市外资股（H股）股票并在香港联交所主板 挂牌上市。公司将充分考虑现有股东的利益和境内外资本市场的情况，在股东会决议有效期内选择适当 的时机和发行窗口完成本次发行并上市。 ...

迈瑞医疗公告，公司于2025年10月14日召开第八届董事会第十四次会议，审议通过了《关于公司发行H 股股票并在香港联合交易所有限公司上市的议案》等相关议案。为满足公司业务发展需要，深入推进国 际化战略，打造国际化资本运作平台，进一步提升公司资本实力，公司拟发行境外上市外资股（H股） 股票并在香港联合交易所有限公司主板挂牌上市。公司将充分考虑现有股东的利益和境内外资本市场的 情况，在股东会决议有效期内选择适当的时机和发行窗口完成本次发行并上市。本次发行并上市尚需提 交公司股东会审议，并需要取得中国证券监督管理委员会、香港证券及期货事务监察委员会和香港联交 所等相关政府部门、监管机构、证券交易所的批准、核准或备案。 ...

Core Viewpoint - Huada Technology Co., Ltd. (沪电股份) is planning a potential Hong Kong IPO with a target fundraising amount of at least $1.5 billion to optimize its overseas business layout and diversify financing channels [1][2]. Group 1: IPO Plans - Huada Technology is collaborating with banks for a potential Hong Kong listing, with the issuance scale and timing still under discussion [1]. - The company has selected China International Capital Corporation (中金公司) and HSBC to manage the stock issuance [1]. Group 2: Business Performance - In the first half of 2025, Huada Technology's export revenue reached 6.893 billion yuan, a year-on-year increase of 48.59%, accounting for 81.16% of total revenue [2]. - The company has been recognized as one of the top brands in the PCB industry, consistently listed among the top 100 PCB companies by various industry associations and research institutions [1]. Group 3: Investment and Expansion - In 2022, Huada Technology invested $280 million to establish a manufacturing facility in Thailand, which commenced operations on April 1, 2023 [2]. - The Thailand production base is expected to enter small-scale production in the second quarter of 2025 [2].

Core Viewpoint - The company, Guomin Technology, is facing regulatory scrutiny from the China Securities Regulatory Commission (CSRC) regarding its overseas listing application, requiring additional legal opinions and clarifications on several compliance matters [1][2]. Company Overview - Guomin Technology submitted its prospectus to the Hong Kong Stock Exchange in June, aiming for a main board listing, with CITIC Securities as its sole sponsor [2]. - The company is a platform-based integrated circuit design firm, ranking among the top five Chinese companies in the global platform MCU market and first in the Chinese MCU market with built-in commercial encryption algorithms [2]. - In addition to its chip business, Guomin Technology is also developing lithium battery anode materials, focusing on artificial graphite and exploring various technological routes for applications in electric vehicles and energy storage systems [2]. Financial Performance - For the fiscal years ending December 31, the company reported revenues of RMB 1.195 billion in 2022, RMB 1.037 billion in 2023, and an estimated RMB 1.168 billion in 2024 [3][5]. - The company has experienced continuous losses, with net losses of RMB 0.19 billion in 2022, RMB 5.94 billion in 2023, and an estimated RMB 2.56 billion in 2024, totaling over RMB 800 million in losses over three years [5][6]. Regulatory Compliance - The CSRC has requested clarifications on four key compliance issues, including the legality of the company's establishment and shareholding changes, the status of overseas reinvestment reporting, potential restrictions on overseas listings, and the alignment of business operations with foreign investment regulations [1]. Executive Actions - Notably, several key executives of Guomin Technology sold shares shortly before the company's application to the Hong Kong Stock Exchange, indicating potential concerns about the company's future performance [6].

Core Viewpoint - Company is actively pursuing the issuance of H-shares and listing on the Hong Kong Stock Exchange, with the listing committee having reviewed the application but not yet granting formal approval [2] Group 1: H-Share Issuance - Company announced the progress of its application for issuing H-shares and listing on the main board of the Hong Kong Stock Exchange [2] - The listing hearing was held on October 9, 2025, and the company received a letter from the exchange on October 10, 2025, indicating that the application was reviewed but not formally approved [2] - The Hong Kong Stock Exchange retains the right to provide further comments on the company's listing application [2] Group 2: Sales Performance - In September, the company's new energy vehicle sales reached 44,678 units, representing a year-on-year increase of 19.44% [2] - Cumulative sales for the year amounted to 304,629 units, showing a year-on-year decline of 3.82% [2] - The company's automotive segment sold 41,249 units in September, up 15.14% year-on-year, while cumulative sales for the year were 276,203 units, down 5.72% year-on-year [2] Group 3: Acquisition - The wholly-owned subsidiary completed the acquisition of a 10% stake in Shenzhen Yingwang Intelligent Technology Co., held by Huawei, for a total transaction price of RMB 11.5 billion [2]

Group 1 - The company, Shanghai Cambridge Technology Co., Ltd., is in the process of applying for the issuance of overseas listed foreign shares (H shares) and plans to list on the Main Board of the Hong Kong Stock Exchange [1][2] - The listing hearing by the Hong Kong Stock Exchange Listing Committee took place on October 9, 2025, to review the company's application for the issuance and listing [1] - The exclusive sponsor of the company's issuance received a letter from the Hong Kong Stock Exchange on October 2, 2025, indicating that the application has been reviewed, but this does not constitute formal approval for listing [1] Group 2 - The company still needs to obtain final approvals from the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, indicating that there is uncertainty regarding the matter [2] - The company will fulfill its information disclosure obligations in accordance with the progress of this matter, urging investors to pay attention to investment risks [2]